Navigation Links
Oncothyreon files investigational new drug application for PX-866 oncology compound
Date:5/1/2008

d single agent in vivo anti-tumor activity and work well in combination with other agents in a number of human tumor models.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit http://www.oncothyreon.com.

Forward Looking Statements

In order to provide Oncothyreon's investors with an understanding of its current intentions and future prospects, this release contains statements that are forward looking, including statements related to future clinical development plans for PX-866. These forward-looking statements represent Oncothyreon's intentions, plans, expectations and beliefs and are based on its management's experience and assessment of historical and future trends and the application of key assumptions relating to future events and circumstances.

Forward-looking statements involve risks and uncertainties, including risks and uncertainties related to Oncothyreon's business and the general economic environment. Many of these risks and uncertainties are beyond Oncothyreon's control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements. Risks, uncertainties, and assumptions include those predicting the timing, duration and results of clinical trials, the timing and results of regulatory reviews, and the safety and efficacy of PX-866. There can be no guarantee that the results of preclinical studies or of early clinical trials will be predictive of either safety or efficacy in future clinical trials. These and other risks and uncertainties are described in the reports and other do
'/>"/>

SOURCE Oncothyreon Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Data for Oncothyreons PX-12 and PX-866 presented at AACR Annual Meeting
2. Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting
3. Oncothyreon announces effectiveness of shelf registration statement
4. Oncothyreon announces issuance of patent for PX-867
5. Oncothyreon to present at upcoming investment conferences
6. Oncothyreon reports full year and fourth quarter 2007 financial results
7. Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call
8. Oncothyreons PX-478 is effective in preclinical model of human lung cancer
9. Oncothyreon launches new corporate website
10. Oncothyreon to present at BIO CEO & Investor Conference
11. Oncothyreon highlights corporate and clinical objectives for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015   PureTech , a science and ... disruptive products and technologies in the healthcare sector, announced ... CEO and Member of the Board of Directors of ... "It,s has been a pleasure to know Chris for ... will be working together more closely now," said Dr. ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... motions for judgment notwithstanding the verdict, a new trial, ...
(Date:2/26/2015)... , Feb. 26, 2015 /PRNewswire/ - SQI Diagnostics ... a life sciences company that develops and commercializes proprietary ... its financial and operational results for the fiscal first ... press release are in Canadian dollars (CAD), unless otherwise ... continued to win new business from our existing customers ...
(Date:2/26/2015)... Feb. 26, 2015   Regulus Therapeutics Inc . ... the discovery and development of innovative medicines targeting microRNAs, ... President and Chief Executive Officer of Regulus, will present ... th Annual Healthcare Conference on Wednesday, March 4, ... held at the Boston Marriott Copley Place.  ...
Breaking Biology Technology:Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... , , ANN ARBOR, ... the release of Oncomine Research Edition version 4.2, a ... Since its inception, Compendia has been fully committed to ... new version of Oncomine features a completely redesigned user-interface, ...
... BRIDGEWATER, N.J., Sept. 23 Advanced Health Media LLC ... and commercial compliance management software for the pharmaceutical industry, announced ... 500 List of Top Technology Innovators Across America for ... this prestigious list of the country,s most innovative developers of ...
... ATLANTA, Sept. 23 MedShape Solutions, Inc. announced today ... orthopedics using proprietary shape memory PEEK Altera(TM) material. The ... be released to select U.S. markets in the coming months. ... in the field of orthopedics. These devices range from ...
Cached Biology Technology:Compendia Bioscience Announces the Release of Oncomine 4 Research Edition 2Advanced Health Media Named to 2009 InformationWeek 500 List of Top Technology Innovators Across America 2Advanced Health Media Named to 2009 InformationWeek 500 List of Top Technology Innovators Across America 3Advanced Health Media Named to 2009 InformationWeek 500 List of Top Technology Innovators Across America 4MedShape Solutions, Inc. Announces First FDA-cleared Shape Memory PEEK Device; Closing of $10M Equity Offering 2
(Date:2/5/2015)... , Jan. 26, 2015 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... corporate website ( http://www.nxt-id.com/ ) as part of its ... wallet. The Company launched its new consumer website for ... Pereira , CEO of NXT-ID said, "Our new corporate ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
(Date:2/5/2015)... DUBLIN , Jan. 28, 2015 Research ... announced the addition of the "Global Biometrics ... Use, Regions and Countries " report to their ... market, Asia-Pacific is anticipated ... by 2015, owing to increasing government spending towards ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3
... University (ASU) and China,s Sun Yat-Sen University (SYSU) ... early and predictive diagnostics to improve patient outcomes ... Leland Hartwell, PhD, and Chief Scientist at the ... agreement with Dr. Jianping Wang, Director of the ...
... New research shows that chondroitin sulfate significantly decreased pain ... of the hand compared with those in the placebo ... Arthritis & Rheumatism, a journal published by ... (ACR), also report that chondroitin sulfate improves grip strength ...
... SEPTEMBER 6, 2011 -- Measuring the emission of greenhouse gases ... That,s the conclusion of a study in the Sept.-Oct. issue ... of farm practices such as tillage on the greenhouse gas, ... than on a more conventional per area basis produced very ...
Cached Biology News:ASU and China's Sun Yat-Sen University to develop early diagnostics against colorectal cancer 2ASU and China's Sun Yat-Sen University to develop early diagnostics against colorectal cancer 3Chondroitin sulfate improves hand function, relieves morning stiffness caused by osteoarthritis 2Study finds crop performance matters when evaluating greenhouse gas emissions 2
... Glutathion-S-transferases (GST) are a group ... the detoxification processes. The GSTs are ... Pi, Teta and microsomal. The classes ... and s Sample Size: ...
... is taking automated patch clamping to a new ... to generate thousands of high quality data points ... in ion channel drug discovery and safety testing. ... afforded by conventional patch clamping can now be ...
... screening and binding optimization and built on ... synthesis platform. These microarrays are available as ... Service. Probe Content Our ... than 1500 known aptamer sequences. Add up ...
... DNA aptamer screening and binding optimization and ... microfluidic on-chip synthesis platform. These microarrays are ... Aptamer Microarray Service. Probe Content ... greater than 1500 known aptamer sequences. Add ...
Biology Products: